Developing a test to predict early treatment failure in follicular lymphoma
Assay Development and Prognostic Model for Predicting Early Clinical Failure in Follicular Lymphoma
This study is looking to help doctors better predict which patients with follicular lymphoma might not respond well to standard treatment, using a special test on tissue samples to find important genetic clues, so they can create more personalized treatment plans for you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-10947165 on NIH RePORTER |
What this research studies
This research focuses on improving the ability to predict early clinical failure in patients with follicular lymphoma, a common type of non-Hodgkin lymphoma. By refining a gene expression assay that analyzes tissue samples, the study aims to identify patients who are at risk of not responding well to standard immunochemotherapy treatment. The approach utilizes advanced technology to analyze genetic markers in biopsies, which could help tailor treatment plans more effectively. Patients will be monitored to see if they achieve a specific event-free survival status after treatment, which is crucial for determining their long-term outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with symptomatic or high-tumor burden follicular lymphoma who are starting immunochemotherapy.
Not a fit: Patients with asymptomatic or low-tumor burden follicular lymphoma who are being managed by observation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate predictions of treatment outcomes, allowing for personalized treatment strategies that improve patient survival rates.
How similar studies have performed: Previous research has shown promise in using gene expression signatures to predict treatment outcomes in various cancers, suggesting that this approach may be effective for follicular lymphoma as well.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Rimsza, Lisa — University of Arizona
- Study coordinator: Rimsza, Lisa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.